4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/302% above fair value
$12.23+0.12 (+0.95%)
Close on Nov 13, 2026Market cap $882.76MP/E –Yield –
4D Molecular Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
4D Molecular Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$166.28M. For fiscal 2025 it was -$109.08M. The highest annual figure on record is -$36.71M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$109.08M | – |
| FY2024 | Dec 31, 2024 | -$134.59M | – |
| FY2023 | Dec 31, 2023 | -$75.79M | – |
| FY2022 | Dec 31, 2022 | -$86.69M | – |
| FY2021 | Dec 31, 2021 | -$69.13M | – |
| FY2020 | Dec 31, 2020 | -$50.91M | – |
| FY2019 | Dec 31, 2019 | -$36.71M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$56.71M | – |
| Q2 FY2026 | Jun 30, 2026 | -$70.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$68.13M | – |
| Q4 FY2025 | Dec 31, 2025 | $28.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$43.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.76M | – |
| Q4 FY2024 | Dec 31, 2024 | -$45.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.24M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.07M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.55M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.84M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.21M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.50M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.37M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.87M | – |
See a number that looks wrong?